article

FILE - A girl receives a vaccine in Manaus, Amazonas State, Brazil, on Feb. 22, 2024. (Photo by MICHAEL DANTAS/AFP via Getty Images)

A novel vaccine designed to target one of the most common cancer-driving mutations in patients with pancreatic and colorectal cancer is showing promising results, according to a recently published study.

Researchers from the University of California said patients "developed strong immune responses" to the new vaccine and "remained disease-free."

Phase 1 trial

Dig deeper:

The vaccine, called ELI-002 2P, showed evidence of triggering a powerful and lasting immune response.

It may also help prevent or delay cancer regrowth in high-risk patients with tumors that are driven by KRAS mutations, according to a UCLA Health news release.

The study, p

See Full Page